GENETIC TESTING FOR HEREDITARY CANCER
|
|
- Ambrose Jackson
- 5 years ago
- Views:
Transcription
1 Oxfrd UnitedHealthcare Oxfrd Clinical Plicy GENETIC TESTING FOR HEREDITARY CANCER Plicy Number: DIAGNOSTIC T2 Effective Date: Octber 1, 2018 Table f Cntents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE... 1 BENEFIT CONSIDERATIONS... 2 COVERAGE RATIONALE... 2 DEFINITIONS... 4 APPLICABLE CODES... 5 DESCRIPTION OF SERVICES... 6 CLINICAL EVIDENCE... 7 U.S. FOOD AND DRUG ADMINISTRATION REFERENCES POLICY HISTORY/REVISION INFORMATION Related Plicy Preventive Care Services INSTRUCTIONS FOR USE This Clinical Plicy prvides assistance in interpreting Oxfrd benefit plans. Unless therwise stated, Oxfrd plicies d nt apply t Medicare Advantage members. Oxfrd reserves the right, in its sle discretin, t mdify its plicies as necessary. This Clinical Plicy is prvided fr infrmatinal purpses. It des nt cnstitute medical advice. The term Oxfrd includes Oxfrd Health Plans, LLC and all f its subsidiaries as apprpriate fr these plicies. When deciding cverage, the member specific benefit plan dcument must be referenced. The terms f the member specific benefit plan dcument [e.g., Certificate f Cverage (COC), Schedule f Benefits (SOB), and/r Summary Plan Descriptin (SPD)] may differ greatly frm the standard benefit plan upn which this Clinical Plicy is based. In the event f a cnflict, the member specific benefit plan dcument supersedes this Clinical Plicy. All reviewers must first identify member eligibility, any federal r state regulatry requirements, and the member specific benefit plan cverage prir t use f this Clinical Plicy. Other Plicies may apply. UnitedHealthcare may als use tls develped by third parties, such as the MCG Care Guidelines, t assist us in administering health benefits. The MCG Care Guidelines are intended t be used in cnnectin with the independent prfessinal medical judgment f a qualified health care prvider and d nt cnstitute the practice f medicine r medical advice. CONDITIONS OF COVERAGE Applicable Lines f Business/ Prducts This plicy applies t Oxfrd Cmmercial plan membership. Benefit Type General Benefits Package Referral Required N (Des nt apply t nn-gatekeeper prducts) Authrizatin Required Yes 1 (Precertificatin always required fr inpatient admissin) Precertificatin with Medical Directr Review Required Yes 1 Applicable Site(s) f Service (If site f service is nt listed, Medical Directr review is required) Special Cnsideratins Labratry 1 Precertificatin with review by a Medical Directr r their designee is required. Genetic Testing fr Hereditary Cancer Page 1 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
2 BENEFIT CONSIDERATIONS Befre using this plicy, please check the member specific benefit plan dcument and any federal r state mandates, if applicable. Essential Health Benefits fr Individual and Small Grup Fr plan years beginning n r after January 1, 2014, the Affrdable Care Act f 2010 (ACA) requires fully insured nn-grandfathered individual and small grup plans (inside and utside f Exchanges) t prvide cverage fr ten categries f Essential Health Benefits ( EHBs ). Large grup plans (bth self-funded and fully insured), and small grup ASO plans, are nt subject t the requirement t ffer cverage fr EHBs. Hwever, if such plans chse t prvide cverage fr benefits which are deemed EHBs, the ACA requires all dllar limits n thse benefits t be remved n all Grandfathered and Nn-Grandfathered plans. The determinatin f which benefits cnstitute EHBs is made n a state by state basis. As such, when using this plicy, it is imprtant t refer t the member specific benefit plan dcument t determine benefit cverage. COVERAGE RATIONALE Genetic cunseling is strngly recmmended prir t these tests in rder t infrm persns being tested abut the advantages and limitatins f the test as applied t a unique persn. Hereditary Breast and Ovarian Cancer (BRCA1/BRCA2) Genetic testing fr BRCA1 and BRCA2 fr individuals with a persnal histry f a related cancer is prven and/r medically necessary in the fllwing situatins: Men with a persnal histry f Breast Cancer. Wmen with a persnal histry f Ovarian Cancer. Wmen with a persnal histry f Breast Cancer in any f the fllwing situatins: Metastatic Breast Cancer and may be a candidate fr treatment with a PARP inhibitr (e.g., laparib). Breast Cancer diagnsed at any age in an individual with at least ne clse (1st-, 2nd-, and 3rd-degree relative) bld relative wh has a BRCA1 r BRCA2 mutatin. Breast Cancer diagnsed at any age in an individual with Ashkenazi Jewish ancestry. Breast Cancer diagnsed at any age with any ne f the fllwing: At least ne clse bld relative with Ovarian Cancer; r At least ne clse male bld relative with Breast Cancer; r At least ne clse bld relative with Breast Cancer diagnsed at age 50 r yunger; r At least tw Clse Bld Relatives n the same side f the family with with Breast Cancer, pancreatic cancer, r prstate cancer at any age; r An unknwn r Limited Family Histry (see Definitins sectin fr further clarificatin f Limited Family Histry). Breast Cancer diagnsed at age 45 r yunger. Triple-Negative (Her2 negative, ER negative and PR negative) Breast Cancer diagnsed at age 60 r yunger. Breast Cancer diagnsed at age 50 r yunger with any f the fllwing: An additinal Breast Cancer primary (prir diagnsis r bilateral cancer); r At least ne clse bld relative with Breast Cancer r pancreatic cancer r prstate cancer; r An unknwn r Limited Family Histry (see Definitins sectin fr further clarificatin f Limited Family Histry). A persnal histry f pancreatic cancer in the any f the fllwing situatins: Pancreatic cancer diagnsed at any age in an individual with at least ne clse bld relative wh has a knwn BRCA1 r BRCA2 mutatin. Pancreatic cancer diagnsed at any age with any ne f the fllwing: At least ne clse relative with Ovarian Cancer; r At least ne clse relative with Breast Cancer diagnsed with at age 50 r yunger; r At least tw Clse Bld Relatives n the same side f the family with Breast Cancer, pancreatic cancer, r prstate cancer; r An unknwn r Limited Family Histry. Men with a persnal histry f prstate cancer in any f the fllwing situatins: Metastatic prstate cancer (radigraphic evidence f metastases r bipsy-prven disease) diagnsed at any age. High Risk prstate cancer (Gleasn Scre at least 7) diagnsed at any age with any f the fllwing: At least ne clse bld relative with Ovarian Cancer at any age r At least ne clse bld relative with Breast Cancer diagnsed at age 50 r yunger; r At least tw clse relatives n the same side f the family with breast, pancreatic and/r prstate cancer; r An unknwn r Limited Family Histry. Genetic Testing fr Hereditary Cancer Page 2 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
3 Individuals with a BRCA ½ pathgenic mutatin detected in tumr tissue. Genetic testing fr BRCA1 and BRCA2 fr individuals withut a persnal histry f a related cancer is prven and/r medically necessary in the fllwing situatins: When there is a knwn BRCA1/BRCA2 mutatin in a clse bld relative (defined as first-, secnd- r third-degree relative). When there is at least ne f the fllwing familial risk factrs: At least ne first- r secnd-degree bld relative meeting any f the abve criteria fr individuals with a persnal histry f a related cancer; r At least ne third-degree bld relative with Breast Cancer and/r Ovarian Cancer wh has at least 2 Clse Bld Relatives with Breast Cancer (at least ne with Breast Cancer at age 50 r yunger) and/r Ovarian Cancer. Genetic testing fr BRCA1 and/r BRCA2 testing is unprven and/r nt medically necessary fr all ther indicatins including: Screening fr breast r Ovarian Cancer risk fr individuals nt listed in the prven indicatins abve; r Risk assessment f ther cancers; r Cnfirmatin f direct t cnsumer genetic testing withut meeting any f the prven indicatins abve. Further evidence is needed t establish the clinical utility f testing in ther ppulatins. Multi-Gene Hereditary Cancer Panel Testing Criteria Genetic testing with a multi-gene hereditary cancer panel in individuals with an indicatin fr testing fr hereditary breast and Ovarian Cancer is prven and/r medically necessary if all f the fllwing criteria are met: The suspected hereditary cancer syndrmes can be diagnsed by testing f ne r mre genes included in the specific hereditary cancer panel; and The results f testing will directly impact this patient s medical management; and The individual meets at least ne f the criteria in Hereditary Breast and Ovarian Cancer (BRCA1/BRCA2) (see abve sectin); and The individual has a family histry r persnal histry that is strngly suggestive f mre than ne hereditary cancer syndrme including at least ne f the fllwing: A persnal histry f at least tw different cancers (e.g., Breast Cancer and Ovarian Cancer). A persnal histry f cancer diagnsed at age 40 r yunger. A persnal histry f cancer and at least ne relative with a cancer assciated with Lynch Syndrme (i.e., brain, clrectal, endmetrial, gastric, varian, pancreatic, renal pelvis, small intestine, r ureter cancers, sebaceus adenmas, sebaceus carcinmas, and keratacanthmas). At least ne clse bld relative diagnsed with Breast Cancer, Ovarian Cancer, prstate cancer r pancreatic cancer at age 40 r yunger. At least three Clse Bld Relatives n the same side f the family diagnsed with any cancer. Genetic testing with a multi-gene cancer panel in individuals with an indicatin fr testing fr hereditary clrectal cancer is prven and/r medically necessary in the fllwing situatins: The suspected hereditary cancer syndrmes can be diagnsed by testing f ne r mre genes included in the specific hereditary cancer panel; and The results f testing will directly impact this individual s medical management; and The individual has a persnal r family histry with at least ne f the fllwing criteria fr Hereditary Clrectal Cancer/Lynch Syndrme Cancer r clrectal plypsis syndrme: Men with a persnal histry f clrectal cancer r wmen with a persnal histry f clrectal r endmetrial cancer diagnsed at age 50 r yunger. Men with a persnal histry f clrectal cancer r wmen with a persnal histry f clrectal r endmetrial cancer diagnsed at age 51 r later with at least ne f the fllwing criteria: A persnal histry f anther cancer assciated with Lynch Syndrme (i.e., brain, gastric, varian, pancreatic, renal pelvis, small intestine, r ureter cancers, sebaceus adenmas, sebaceus carcinmas, and keratacanthmas); r Tumr testing results shwing that their clrectal r endmetrial cancer was MSI-high r had immunhistchemical (IHC) staining shwing the absence f ne r mre mismatch repair prteins (MLH1, MSH2, MSH6 r PMS2) A persnal histry f clrectal plypsis with at least 10 adenmatus plyps, at least 2 hamartmatus plyps, r at least 5 serrated plyps. At least ne clse bld relative with a diagnsis f clrectal cancer r endmetrial cancer at age 50 r yunger. Genetic Testing fr Hereditary Cancer Page 3 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
4 At least ne clse bld relative with at least tw cancers assciated with Lynch Syndrme (i.e., brain, clrectal, endmetrial, gastric, varian, pancreatic, renal pelvis, small intestine, r ureter cancers, sebaceus adenmas, sebaceus carcinmas, and keratacanthmas). Tw r mre Clse Bld Relatives with a cancer assciated with Lynch Syndrme (i.e., brain, clrectal, endmetrial, gastric, varian, pancreatic, renal pelvis, small intestine, r ureter cancers, sebaceus adenmas, sebaceus carcinmas, and keratacanthmas), with at least ne diagnsed at age 50 r yunger. Three r mre Clse Bld Relatives with a cancer assciated with Lynch Syndrme (i.e., brain, clrectal, endmetrial, gastric, varian, pancreatic, renal pelvis, small intestine, r ureter cancers, sebaceus adenmas, sebaceus carcinmas, and keratacanthmas) diagnsed at any age. At least ne clse bld relative with a clinical diagnsis f Familial Adenmatus Plypsis, Attenuated Familial Adenmatus Plypsis, Juvenile Plypsis Syndrme, r Peutz-Jeghers Syndrme. A PREMM5, PREMM1,2,6, MMRpr, r MMRpredict Scre f 5% r greater fr having a Lynch syndrme gene mutatin. Genetic testing with a multi-gene hereditary cancer panel in individuals withut an indicatin fr testing fr hereditary breast and Ovarian Cancer r clrectal cancer is prven and/r medically necessary in the fllwing situatins: The suspected hereditary cancer syndrmes can be diagnsed by testing f ne r mre genes included in the specific hereditary cancer panel; and The results f testing will directly impact this individual s medical management; and The individual has a family histry r persnal histry that is strngly suggestive f mre than ne hereditary cancer syndrme. Genetic testing with a multi-gene hereditary cancer panel in individuals diagnsed with cancer at age 18 r yunger is prven and/r medically necessary. Genetic testing with a multi-gene cancer panel is prven and/r medically necessary in an individual wh has previusly tested negative (indeterminate) fr the high Penetrance genes that are mst likely t explain the persnal r family histry f cancer (e.g., BRCA1/2 fr Breast Cancer and Ovarian Cancer)in the fllwing situatins: The suspected hereditary cancer syndrmes can be diagnsed by testing f ne r mre genes included in the specific hereditary cancer panel; and The results f testing will directly impact this individual s medical management; and The individual s persnal and family histry remains strngly suggestive f an inherited susceptibility that can be diagnsed by testing f ne r mre genes included in the specific hereditary cancer panel including at least ne f the fllwing: A persnal histry f at least tw different cancers (e.g., Breast Cancer and Ovarian Cancer). A persnal histry f cancer diagnsed at age 40 r yunger. A persnal histry f cancer and at least ne relative with a cancer assciated with Lynch Syndrme (i.e., brain, clrectal, endmetrial, gastric, varian, pancreatic, renal pelvis, small intestine, r ureter cancers, sebaceus adenmas, sebaceus carcinmas, and keratacanthmas). At least ne clse bld relative diagnsed with Breast Cancer, Ovarian Cancer, prstate cancer r pancreatic cancer at age 40 r yunger. At least three Clse Bld Relatives n the same side f the family diagnsed with any cancer. Multi-gene hereditary cancer panels are unprven and/r nt medically necessary fr all ther indicatins. DEFINITIONS Please nte, fr the purpse f this plicy: Age Guidelines: Fr the statements that include Age Guidelines, a persn is cnsidered t be 45 years f age up until the day befre their 46 th birthday, and a persn is cnsidered t be 50 years f age up until the day befre their 51 st birthday. Breast Cancer: Either invasive carcinmas r nn-invasive (in situ) ductal carcinma types. (NCCN 2018) Clse Bld Relatives are defined as fllws (NCCN 2017a): First degree relatives include parents, siblings, and ffspring Secnd degree relatives include half-brthers/sisters, aunts/uncles, grandparents, grandchildren and nieces/nephews affected n the same side f the family Third degree relatives include first cusins, great-aunts/uncles, great-grandchildren and great grandparents affected n same side f family Genetic Testing fr Hereditary Cancer Page 4 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
5 Funder Mutatin: A Funder Mutatin is a gene mutatin bserved with high frequency in a grup that is r was gegraphically r culturally islated, in which ne r mre f the ancestrs were a carrier f the mutant gene. This phenmenn is ften called a Funder effect (Natinal Cancer Institute website). (NCCN 2017a) Gleasn Scring: Gleasn scring is a system f grading prstate cancer tissue based n hw it lks under a micrscpe. Gleasn Scres range frm 2 t 10 and indicate hw likely it is that a tumr will spread. A lw Gleasn Scre means the cancer tissue is similar t nrmal prstate tissue and the tumr is less likely t spread. A high Gleasn Scre means the cancer tissue is very different frm nrmal and the tumr is mre likely t spread. (NCI, 2018b) Limited Family Histry: Defined as having fewer than tw knwn first-degree r secnd-degree female relatives r female relatives surviving beynd 45 years f age n either r bth sides f the family (e.g., individual wh is adpted). (NCCN 2017a) Lynch Syndrme Cancers: Clrectal, endmetrial, gastric, varian, pancreatic, ureter and renal pelvis, brain (usually gliblastma), and small intestinal cancers, and sebaceus adenmas, sebaceus carcinmas, and keratacanthmas as seen in Muire-Trre syndrme. (NCCN, 2017b) Ovarian Cancer: Includes fallpian tube cancers and primary peritneal carcinma. (NCCN, 2018) Penetrance: The prbability f a clinical cnditin develping in the presence f a specific genetic variant/mutatin. (Daly et al. 2017) Persnal and Family Histry Dcumentatin: in the frm f a pedigree drawing/diagram utilizing standardized nmenclature, shuld be in the cntempraneus medical recrds submitted with the testing request (i.e., request frm) (NCCN, 2017b). PREMM (PREdictin Mdel fr gene Mutatins): The PREMM mdel estimates the verall cumulative prbability f having an MLH1, MSH2, MSH6, PMS2, and EPCAM gene mutatin. Triple-Negative Breast Cancer: Refers t any Breast Cancer that des nt shw expressin f estrgen receptrs (ER), prgesterne receptrs (PR) r HER2/neu. (NCCN, 2017a) APPLICABLE CODES The fllwing list(s) f prcedure and/r diagnsis cdes is prvided fr reference purpses nly and may nt be all inclusive. Listing f a cde in this plicy des nt imply that the service described by the cde is a cvered r nncvered health service. Benefit cverage fr health services is determined by the member specific benefit plan dcument and applicable laws that may require cverage fr a specific service. The inclusin f a cde des nt imply any right t reimbursement r guarantee claim payment. Other Plicies may apply. CPT Cde BRCA1 and BRCA BRCA1 and BRCA Descriptin BRCA1, BRCA2 (Breast Cancer 1 and 2) (e.g., hereditary breast and varian cancer) gene analysis; full sequence analysis and full duplicatin/deletin analysis BRCA1, BRCA2 (Breast Cancer 1 and 2) (e.g., hereditary breast and varian cancer) gene analysis; full sequence analysis and cmmn duplicatin/deletin variants in BRCA1 (i.e., exn 13 del 3.835kb, exn 13 dup 6kb, exn del 26kb, exn 22 del 510bp, exn 8-9 del 7.1kb) BRCA1, BRCA2 (Breast Cancer 1 and 2) (e.g., hereditary breast and varian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants BRCA1, BRCA2 (Breast Cancer 1 and 2) (e.g., hereditary breast and varian cancer) gene analysis; uncmmn duplicatin/deletin variants BRCA1 (Breast Cancer 1) (e.g., hereditary breast and varian cancer) gene analysis; full sequence analysis and cmmn duplicatin/deletin variants (i.e., exn 13 del 3.835kb, exn 13 dup 6kb, exn del 26kb, exn 22 del 510bp, exn 8-9 del 7.1kb) BRCA1 (Breast Cancer 1) (e.g., hereditary breast and varian cancer) gene analysis; knwn familial variant Genetic Testing fr Hereditary Cancer Page 5 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
6 CPT Cde Multi-Gene Panel Descriptin BRCA2 (Breast Cancer 2) (e.g., hereditary breast and varian cancer) gene analysis; full sequence analysis BRCA2 (Breast Cancer 2) (e.g., hereditary breast and varian cancer) gene analysis; knwn familial variant Hereditary Breast Cancer-related disrders (e.g., hereditary Breast Cancer, hereditary varian cancer, hereditary endmetrial cancer); genmic sequence analysis panel, must include sequencing f at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53 Hereditary Breast Cancer-related disrders (e.g., hereditary Breast Cancer, hereditary varian cancer, hereditary endmetrial cancer); duplicatin/deletin analysis panel, must include analyses fr BRCA1, BRCA2, MLH1, MSH2, and STK11 Hereditary cln cancer disrders (e.g., Lynch syndrme, PTEN hamartma syndrme, Cwden syndrme, familial adenmatsis plypsis); genmic sequence analysis panel, must include sequencing f at least 10 genes, including APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PTEN, SMAD4, and STK11 Hereditary cln cancer disrders (e.g., Lynch syndrme, PTEN hamartma syndrme, Cwden syndrme, familial adenmatsis plypsis); duplicatin/deletin analysis panel, must include analysis f at least 5 genes, including MLH1, MSH2, EPCAM, SMAD4, and STK11 Hereditary neurendcrine tumr disrders (e.g., medullary thyrid carcinma, parathyrid carcinma, malignant phechrmcytma r paraganglima); genmic sequence analysis panel, must include sequencing f at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL Hereditary neurendcrine tumr disrders (e.g., medullary thyrid carcinma, parathyrid carcinma, malignant phechrmcytma r paraganglima); duplicatin/deletin analysis panel, must include analyses fr SDHB, SDHC, SDHD, and VHL CPT is a registered trademark f the American Medical Assciatin DESCRIPTION OF SERVICES Genetic testing fr hereditary cancer susceptibility is used t predict an individual's risk f cancer develpment in the future. It has been estimated that 5-10% f all cancers are hereditary. (Heald et al. 2016) Hereditary Breast and Ovarian Cancer (BRCA1/BRCA2) Breast Cancer is the secnd mst cmmn cause f cancer-related deaths amng wmen. The inherited tendency t develp breast and varian cancer has been termed the hereditary breast and Ovarian Cancer syndrme (HBOC). Mutatin in either f tw genes, BRCA1 and BRCA2, has been assciated with an increased risk fr Breast Cancer and Ovarian Cancer. A deleterius mutatin in either gene may be inherited frm either parent; and later an acquired mutatin f the ther allele can lead t cancer develpment. It has been estimated that inherited BRCA1 and BRCA2 mutatins accunt fr 5 t 10 percent f Breast Cancers and 10 t 15 percent f Ovarian Cancers amng white wmen in the United States. (Natinal Cancer Institute [NCI], 2015) Harmful BRCA1 mutatin may als increase a wman s risk f develping ther cancers. Men with a harmful BRCA1 mutatin als have an increased risk f Breast Cancer and, pssibly, f pancreatic cancer, testicular cancer, and earlynset prstate cancer. Hwever, male Breast Cancer, pancreatic cancer, and prstate cancer appear t be mre strngly assciated with BRCA2 gene mutatin. (Thmpsn and Eatn, 2002; NCCN, 2017) Multi-Gene Hereditary Cancer Panels Multi-gene hereditary cancer panels using next generatin sequencing technlgy are currently available, and many different test panels are marketed cmmercially, mst f which als include large deletin/duplicatin analysis. These panels are intuitively attractive because they can rapidly test fr numerus mutatins bth within a single gene and acrss multiple genes related t increased cancer risks. It is als pssible that these multi-gene tests can, in the case f families where mre than ne hereditary cancer syndrme is suspected, be perfrmed mre cst effectively than stepwise individual gene testing. Hwever, many f these panel tests als include lw t mderate-risk genes that may result in the identificatin f gene mutatins that are f unclear clinical significance r which wuld nt clearly direct a patient s medical management recmmendatins. Identificatin f mutatins fr which the clinical management is uncertain may lead t unnecessary fllw-up testing and prcedures, all f which have their wn Genetic Testing fr Hereditary Cancer Page 6 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
7 inherent risks. (NCCN 2017a; NCCN 2017b; LaDuca et al., 2014; Rbsn et al., 2015; Kurian et al., 2014; Tung et al., 2015; Pln et al., 2011) CLINICAL EVIDENCE Genetic testing fr hereditary cancer susceptibility is used t predict an individual's risk f cancer develpment in the future. It has been estimated that 5-10% f all cancers are hereditary (Heald et al. 2016). Hereditary cancers typically have an earlier age f nset and have an autsmal dminant pattern f inheritance bservable in a family (NCCN, 2017a). A small subset f these inherited cancers, abut 15-20%, may be the result f a cmplex interactin between multiple genes. (ASCO 2018) T identify if an individual has an increased risk f having a hereditary cancer, it is imprtant t take a detailed family histry that includes first, secnd and third degree relatives that fcuses n cancer diagnses by age f nset, primary site(s), presence f bilateral disease, and current age r age at time f death. Other cnditins that can be a feature f hereditary cancers shuld be nted, as well as medical and surgical histry. The individual shuld have a thrugh physical exam perfrmed by a clinician with familiarity with hereditary cancer syndrme. When applicable, risk assessment tls shuld be utilized t help identify the risk an individual has a hereditary cancer gene (NCCN 2017a). Sme examples f tls include BRCAPRO, the Breast and Ovarian Cancer Analysis f Disease Incidence and Carrier Estimatin Algrithm (BOADICEA) (NCCN 2017a) and Predictin f MLH1 and MSH2 Mdel (PREMM) (NCCN 2017b). Genetic testing is recmmended generally when there is a persnal r family histry cnsistent with a hereditary cancer susceptibility, the test can be adequately interpreted, and the results can be used t diagnse r influence the medical management f the individual r at risk family members. (Rbsn et al. 2015) Table 1 lists cmmn cancers that can be hereditary, the assciated genes, and references that can be utilized t learn abut each hereditary cancer syndrme in mre detail. Hereditary Cancer Syndrme(s) Hereditary breast and varian cancer Familial adenmatus plypsis (FAP) Ataxia-telangiectasia PTEN hamartma tumr syndrme/cwden syndrme Gene(s) BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD51C,RAD51D Ɨ, PTEN, TP53, STK11, NBN, ATM, CDH1 APC ATM PTEN Assciated Cancer(s) and References Breast (Antniu et al. 2003; Chen et al. 2006; Hilgart et al 2012; Shivitz 2015, Daly et al. 2017) Ovarian (Risch et al. 2001; Chen et al. 2006; Lancaster et al 2015) Fallpian tube (Medeirs et al. 2006; Lancaster et al 2015) Primary peritneal (Casey et al. 2005; Finch et al. 2012; Lancaster et al 2015) Pancreatic (BCLC, 1999; van Asperen et al. 2005; Mersch et al 2015) Prstate (Risch et al. 2001; Thmpsn et al. 2002; van Asperen et al. 2005; Mersch et al 2015) Melanma (BCLC, 1999; Mersch et al 2015) Gastric/stmach (BCLC, 1999) Breast (He et al. 2016) Ovarian (Mstwska et al. 2014) Clrectal (Feng et al. 2014; Slwik et al. 2015; Leshn et al. 2016) Pancreatic (Leshn et al. 2016) Skin (Leshn et al. 2016) Thyrid (Septer et al. 2013) Breast (Marabelli et al. 2016) Sarcma (Ballinger et al. 2016) Lung (Bhwmik et al. 2015; Huang et al. 2016) Gastric (Helgasn et al. 2015) Melanma (Antnpulu et al. 2015) Pancreatic (Rberts et al. 2016) Breast (Slattery et al. 2012; Ozturk et al. 2013) Endmetrial (Eng, 2016) Gastric/digestive (Ga et al. 2013) Clrectal (Jing et al. 2014) Thyrid (Eng, 2016) Genetic Testing fr Hereditary Cancer Page 7 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
8 Hereditary Cancer Syndrme(s) Hereditary nnplypsis cln cancer (HNPCC)/Lynch syndrme Peutz-Jeghers syndrme Li-Fraumeni syndrme Hereditary diffuse gastric cancer syndrme Juvenile plypsis syndrme Hereditary mixed plypsis Gene(s) EPCAM, MLH1, MSH2, MSH6, PMS1, PMS2 STK11 (LKB1) TP53 Assciated Cancer(s) and References Breast (Smlarz et al. 2015; Kappil et al. 2016; Stffel et al. 2015; Bland, 2018) Ovarian (Watsn et al. 2008; Bnadna et al. 2011; Auranen, 2011) Clrectal (Senter et al. 2008; Raskin et al. 2011) Hepatcellular (Khlmann and Gruber, 2014) Endmetrial/uterine (Raskin et al. 2011; Castellsagué et al. 2015; Watsn et al. 2008; Renknen-Sinisal, 2007; Auranen, 2011) Breast (Bardman et al. 1998) Ovarian (McGarrity et al. 2016) Clrectal (Slattery et al. 2010) Gastric (Giardiell et al. 1987) Pancreatic (Klein et al. 2001) Breast (Sagne et al. 2013; Mai et al. 2016) Ovarian (Schildkraut et al. 2010) Brain/CNS (Mai et al. 2016) Prstate (Brges and Ayres, 2015) Sarcma (Mai et al. 2016) Thyrid (Chen et al. 2015) CDH1 Breast (Benusigli et al. 2013; Hansfrd et al. 2015) Gastric (Hansfrd et al. 2015) BMPR1A, SMAD4 Gupta et al. (2017) POLD1, GREM1, POLE Gupta et al. (2017) BRCA1/BRCA2 The BRCA1 and BRCA2 genes are assciated with causing HBOC. This syndrme results in an increased risk fr Breast Cancer fr men and wmen, and an increased risk fr Ovarian Cancer in wmen. Other cancers have been assciated with HBOC, particularly with BRCA2 variants, including prstate, pancreatic and melanma. Management f HBOC fr thse with cancer includes bilateral masectmy due t the high risk f Breast Cancer. Treatment f varian and ther cancers is similar t spradic cancers. Preventative measures fr asymptmatic individuals includes prphylactic bilateral masectmy and pherectmy, chempreventin, and increased surveillance. (Petrucelli et al. 2016) Testing fr BRCA1 and BRCA2 can include targeted variants fr at risk ppulatins, such as fr thse with Ashkenazi Jewish ancestry, full gene sequencing, and duplicatin/deletin analysis. BRCA1 accunts fr abut 66% f HBOC, and sequence analysis can identify variants in abut 80% f cases fr bth BRCA1 and BRCA2. Duplicatin/deletin testing identifies variants in each gene in an additinal 10% f cases. (Petrucelli et al. 2016) The Natinal Cmprehensive Cancer Netwrk (NCCN) guidelines present evidence based specific criteria fr genetic testing fr hereditary breast and/r Ovarian Cancer syndrme caused by BRCA1/BRCA2. The guidelines address genetic risk assessment, cunseling, testing and management based n test results (NCCN 2017a). The recmmended NCCN criteria fr testing include: Thse diagnsed with Ovarian Cancer A knwn BRCA1/BRCA2 mutatin in the family Breast Cancer diagnsis < age 50 Triple negative Breast Cancer diagnsed < age 60 Tw Breast Cancer primaries in an individual Breast Cancer at any age with: Mre than ne clse bld relative with Breast Cancer diagnsed age 50 r yunger, r Ovarian Cancer at any age Mre than tw clse bld relatives with Breast Cancer, prstate cancer (Gleasn Scre > 7 r metastatic) r pancreatic cancer at any age Pancreatic cancer at any age Frm an increased risk ppulatin Male Breast Cancer Genetic Testing fr Hereditary Cancer Page 8 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
9 Metastatic prstate cancer Individual with Ashkenazi Jewish Ancestry with breast, varian r pancreatic cancer at any age Individual with a persnal r family histry f three r mre f the fllwing, especially if diagnsed at age 50 r yunger: Multiple primaries in the same persn Breast Cancer Prstate cancer (Gleasn Scre > 7 r metastatic) Other cancers: melanma, sarcma, adrencrtical carcinma, cln cancer, endmetrial cancer, thyrid cancer, kidney cancer, dermtlgical manifestatins f HBOC with macrcephaly, r hamartmatus plyps f the gastrintestinal tract. An individual with n persnal histry f cancer but has a clse relative(s) with ne f the fllwing: a knwn BRCA1/BRCA2 mutatin >= tw breast primaries in an individual Tw clse bld relatives n the same side f the family with at least ne diagnsed at age 50 r yunger Ovarian Cancer Male Breast Cancer First r secnd degree relative with Breast Cancer diagnsed age 45 r yunger Family histry f three r mre f the fllwing, especially if diagnsed at age 50 r yunger: Multiple primaries in the same persn Breast Cancer Prstate cancer (Gleasn Scre >7 r metastatic) Other cancers: melanma, sarcma, adrencrtical carcinma, cln cancer, endmetrial cancer, thyrid cancer, kidney cancer, dermtlgical manifestatins f HBOC with macrcephaly, r hamartmatus plyps f the gastrintestinal tract. In additin, (NCCN recmmends testing an individual in a family with a cancer diagnsis first shuld be discussed. If there are n living family members with breast r Ovarian Cancer available fr testing, cnsider testing family members affected with ther cancers assciated with BRCA1/BRCA2, such as prstate cancer (Gleasn Scre 7 r metastatic), pancreatic cancer r melanma. Due t ptential difficulting in interpreting testing results in an unaffected persn, testing f individuals withut a cancer diagnsis shuld nly be cnsidered when there is n affected family member available fr testing. (NCCN, 2017a) The U.S. Preventive Services Task Frce (Myer, 2014) recmmends that primary care prviders screen wmen wh have family members with breast, varian, tubal r peritneal cancer with ne f several screening tls designed t identify a family histry that may be assciated with an increased risk fr ptentially harmful mutatins in Breast Cancer susceptibility genes (BRCA1 r BRCA2). Tls include the Ontari Family Histry Assessment Tl, Manchester Scring System, Referral Screening Tl, Pedigree Assessment Tl, and FHS-7. Wmen with psitive screening results shuld receive genetic cunseling and, if indicated after cunseling, BRCA testing (Grade B). Screening shuld ccur at age 18, and every 5-10 years after that t assess fr family histry changes. In additin, the USPSTF recmmends against rutine genetic cunseling r BRCA testing fr wmen whse family histry is nt assciated with an increased risk fr ptentially harmful mutatins in the BRCA1 r BRCA2 genes (Grade D). Klr et al. (2017) reviewed medical claims frm fr BRCA testing and resulting interventins amng wmen ages with emplyer spnsred health care. They nted that BRCA testing increased 2.3 times in metrplitan and 3.0 times in nn-metrplitan areas during the study perid. Receipt f preventative services within 90 days f testing als varied between these regins, with the exceptin f mastectmy (6-10% f testers ver the study perid). Wmen were less likely t receive a MRI f the breast in nn-metrplitan areas (8.2% vs. 10.3%), as well as mammgraphy (11.5% vs. 13.8%). Receipt f genetic cunseling befre r after testing was mre cmmn in the metrplitan grup, but in bth grups, an increase was seen ver the study perid frm 5.3-8% in metrplitan areas and % in nn-metrplitan areas. Overtime the disparities between the tw grups was reduced, and the authrs nte that the implementatin f the USPSTF guidelines and the availability f BRCA cunseling and testing under the Affrdable Care Act in September f 2010 may have influenced the increase in test and the reductin in differences between the tw grups. The highest rate f BRCA testing in the study was wmen per 100,000 wmen aged which is cmparable t the estimated prevalence f BRCA mutatins in the general US ppulatin. Of 211 Ashkenazi Jewish Breast Cancer prbands with a family histry f pancreatic cancer, Stadler et al. (2011) fund that 30 (14.2%) harbred a BRCA mutatin. Furteen (47%) f the mutatins were in BRCA1 and 16 (53%) were in BRCA2. Patients diagnsed with Breast Cancer at age 50 years were fund t have a higher BRCA1/2 mutatin prevalence than prbands with Breast Cancer wh were diagnsed at age > 50 years (21.1% vs 6.9%). In patients with a first-, secnd-, r third-degree relative with pancreatic cancer, mutatin prevalence was 15.4%, 15.3% and 8.6%, respectively. The authrs fund that BRCA1 and BRCA2 mutatins are bserved with nearly equal distributin in Ashkenazi Jewish breast-pancreas cancer families, suggesting that bth genes are assciated with Genetic Testing fr Hereditary Cancer Page 9 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
10 pancreatic cancer risk. Ferrne et al. (2009) lked at the prevalence f BRCA1 and BRCA2 in an unselected grup f Jewish patients and cmpared patients with resected BRCA mutatin-assciated pancreatic adencarcinma (PAC) t PAC patients withut mutatins. Of the 187 Jewish patients wh underwent resectin fr PAC, tissue was available fr 145 patients. Funder mutatins fr BRCA1 and BRCA2 were identified in 5.5% f patients (tw with BRCA1 [1.3%] and six with BRCA2 [4.1%]). A previus cancer was reprted by 24% (35 f 145) f patients with the mst cmmn sites being Breast Cancer (9 f 35; 74%) and prstate cancer (8 f 35; 23%). Several studies have shwn that BRCA1 Breast Cancer is mre likely t be characterized as triple-negative. Studies have reprted BRCA1 mutatins in 9-28% f patients with triple-negative Breast Cancer. In additin, it appears that amng patients with triple-negative disease, BRCA mutatin carriers were diagnsed at a yunger age cmpared with nn-carriers. (NCCN 2017a) The triple-negative Breast Cancer phentype, which carries an adverse prgnsis, accunts fr 80% t 90% f BRCA1-assciated Breast Cancers. A study f 54 wmen with triple-negative Breast Cancer aged 40 years r yunger, wh were nt cnsidered candidates fr BRCA testing because f the lack f a strng family histry, shwed five with BRCA1 mutatins and ne with a BRCA2 mutatin (11% mutatin prevalence). (Natinal Cancer Institute 2018a; Yung et al. 2009) In a chrt f triple negative Breast Cancer patients, Gnzalez-Angul et al. (2011) fund a 19.5% incidence f BRCA mutatins. Median age was 51 years (27-83 years). The authrs recmmend that genetic testing be discussed with patients with triple negative Breast Cancer. Almst 10% f wmen with Breast Cancer wh are yunger than age 50 have BRCA mutatins. Mst f the BRCApsitive wmen d nt have persnal r family histries f breast r Ovarian Cancer and are nt f Ashkenazi Jewish ancestry. Using a simulatin mdel, Kwn et al. (2010) evaluated six ppulatins f wmen yunger than 50 with Breast Cancer, lking at csts and health benefits. The results led the authrs t cnclude that testing wmen with triple negative Breast Cancers wh were yunger than 50 years fr BRCA mutatins shuld be adpted int current guidelines fr genetic testing. The prevalence f BRCA1/2 LRs was investigated in 48,456 patients with diverse clinical histries and ancestries that were referred fr clinical mlecular testing fr suspicin f hereditary breast and Ovarian Cancer. Prevalence data was analyzed fr patients frm different risk and ethnic grups. Patients were designated as high-risk (n=25,535) if their clinical histry predicted a high prir prbability. Fr these patients, large rearrangement (LR) testing was perfrmed autmatically in cnjunctin with sequencing. Elective patients (n=22,921) did nt meet the high-risk criteria, but underwent LR testing if BRCA1/2 sequencing indicated n knwn mutatins. Overall BRCA1/2 mutatin prevalence amng high-risk patients was 23.8% versus 8.2% fr the elective grup. The mutatin prfile fr highrisk patients was 90.1% sequencing mutatins versus 9.9% LRs, and fr elective patients, 94.1% sequencing versus 5.9% LRs. The authrs nted that this difference may reflect the bias in high-risk patients t carry mutatins in BRCA1, which has a higher penetrance and frequency f LRs cmpared with BRCA2. Significant differences in the prevalence and types f LRs were fund in patients f different ancestries. LR mutatins were significantly mre cmmn in Latin American/Caribbean patients. (Judkins et al., 2012) A study (Walsh 2006) fund that the nly genetic test cmmercially available in the United States t determine risk fr develpment f hereditary Breast Cancer failed t detect BRCA1 and BRCA2 mutatins in apprximately 12% f Breast Cancer patients (n=300) wh were members f a family with at least fur cases f Breast Cancer and/r Ovarian Cancer. In this study, researchers retested participants fr carrier status f genetic mutatins knwn t influence risk fr develpment f Breast Cancer using a mlecular methd nt currently cleared fr market in the United States knwn as multiplex ligatin-dependent prbe amplificatin (MLPA). Prir t enrllment, all participants had received a negative result frm the Breast Cancer genetic test (Myriad Genetics Inc.) used rutinely in the United States. The results f MLPA analysis indicated that 17% f study participants were, in fact, carriers f Breast Cancer-relevant genetic mutatin, with 12% fund t have alteratins f BRCA1 r BRCA2. Inherited alteratins f BRCA1 were mre frequent amng participants wh were diagnsed with Breast Cancer prir t 40 years f age (16%) than amng thse wh were lder when diagnsed (6.5%). The clinical implicatins f these findings cannt be generalized t ther ppulatins, but results strngly suggest that imprved methds fr determining Breast Cancer risk are needed fr individuals with strng family histries f breast and/r Ovarian Cancer. Unger et al. (2000) assessed the frequency f genmic rearrangements in BRCA1 was in 42 American families with breast and Ovarian Cancer wh were seeking genetic testing and wh were subsequently fund t be negative fr BRCA1 and BRCA2 cding-regin mutatins. The exn 13 duplicatin was detected in ne family, and fur families had ther genmic rearrangements. A ttal f 5 (11. 9%) f the 42 families with breast/ovarian Cancer wh did nt have Genetic Testing fr Hereditary Cancer Page 10 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
11 BRCA1 and BRCA2 cding-regin mutatins had mutatins in BRCA1 that were missed by cnfrmatin-sensitive gel electrphresis r sequencing. Fur f five families with BRCA1 genmic rearrangements included at least ne individual with bth breast and Ovarian Cancer; therefre, fur (30.8%) f 13 families with a case f multiple primary breast and Ovarian Cancer had a genmic rearrangement in BRCA1. Families with genmic rearrangements had prir prbabilities f having a BRCA1 mutatin, ranging frm 33% t 97% (mean 70%). In cntrast, in families withut rearrangements, prir prbabilities f having a BRCA1 mutatin ranged frm 7% t 92% (mean 37%). Prfessinal Scieties American Cllege f Obstetricians and Gyneclgists (ACOG) In a 2009 practice bulletin (reaffirmed 2015), the ACOG recmmended criteria fr genetic risk assessment f hereditary breast and Ovarian Cancer syndrme (HBOC). These recmmendatins cnclude: BRCA psitive wmen shuld be ffered salping-phrectmy by age 40 r when childbearing is cmpleted. Fr a risk reducing bilateral salping-phrectmy, all tissue frm the varies and fallpian tubes shuld be remved. Thrugh visualizatin f the peritneal surfaces with pelvic washings shuld be perfrmed. Cmplete, serial sectining f the varies and fallpian tubes is necessary, with micrscpic examinatin fr ccult cancer. Genetic risk assessment is recmmended fr patients with a greater than an apprximate 20-25% chance f having an inherited predispsitin t Breast Cancer and Ovarian Cancer. This includes wmen with the fllwing: A clse relative (mther, sister, daughter, grandmther, granddaughter, aunt r niece) with a knwn BRCA mutatin Persnal histry f bth breast and Ovarian Cancer Ovarian Cancer and a clse relative with Ovarian Cancer r premenpausal Breast Cancer r bth Ovarian Cancer and Ashkenazi Jewish ancestry Breast Cancer by age 40 years and Ashkenazi Jewish ancestry Breast Cancer by age 50 years and a clse relative with Ovarian Cancer r male Breast Cancer Additinally, in a 2017 Cmmittee Opinin (ACOG 2017), ACOG recmmends that wmen with a strng family histry f varian, breast, r cln cancer may have a BRCA mutatin r Lynch Syndrme, and shuld be referred fr frmal genetic cunseling t assess their cancer risk, and if apprpriate, be ffered testing. American Sciety f Clinical Onclgy (ASCO) An ASCO plicy statement recmmends that genetic testing fr cancer susceptibility be perfrmed when the fllwing three criteria are met: the individual being tested has a persnal r family histry suggestive f genetic cancer susceptibility; the test can be adequately interpreted; and the test results have accepted clinical utility. (Rbsn et al., 2015) Natinal Sciety f Genetic Cunselrs (NSGC) The NSGC recmmends that genetic testing be perfrmed in the cntext f an infrmed decisin-making prcess. (Berliner et al., 2013) The prcess f cancer risk assessment and genetic cunseling fr hereditary breast and Ovarian Cancer syndrme requires many steps, including the fllwing: Gathering persnal medical and family histry data Psychscial assessment Discussin f cancer and mutatin risk and hw persnalized risk estimates are derived Facilitatin f the infrmed cnsent prcess thrugh discussin f the risks, benefits, limitatins, and likelihd f identifying a mutatin with genetic susceptibility testing Results disclsure (if applicable) Discussin f medical management ptins Review f issues related t genetic discriminatin Multi-Gene Hereditary Cancer Panels Multi-gene hereditary cancer panels can be used t investigate varius cancers thrugh the use f evaluating multiple genes simultaneusly. In sme situatins, the use f a multi-gene panel test may result in a cst and time efficient apprach. This is mst useful where multiple high-penetrance genes with actinable results are pssible because it is difficult t predict which gene is mst likely t be mutated based n persnal r family medical histry (Rbsn et al. 2015). In a study by Gardner et al. (2018), 630 individuals were tested with a 27-gene inherited cancer panel and 84% had a family histry f cancer. Of these individuals, 65 were determined t have variants classified as pathgenic r likely pathgenic acrss 14 genes (10.3%). Only 42% f these variants ccurred in classic HBOC r Lynch Syndrmeassciated genes, while 58% were bserved in high r mderate t lw risk genes n the panel. The researchers cncluded that there is utility t using multi-gene panels ver single gene testing particularly in thse with an inherited predispsitin t cancer. Genetic Testing fr Hereditary Cancer Page 11 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
12 Daly et al. (2017) prvided an verview t NCCN breast and varian cancer susceptibility screening guideline updates, and Gupta et al. (2017) published insights regarding the NCCN 2017 updated fr susceptibility screening fr clrectal cancer syndrmes, specifically arund multigene cancer panels. They cmmented that multigene testing shuld fcus n clinically actinable genes, and avid the inclusin f lw t mderate risk genes that lack evidence regarding risk management strategies. After review f available evidence, Daly et al. (2017) identified the knwn high and mderate penetrance genes with available guidelines r recmmendatins n risk surveillance and/r management, which included fr breast and varian cancer, BRCA1/2, TP53, and PTEN (high penetrance) and ATM, BRIP1, CDH1, CHEK2, NBN, PALB2, RAD51C, RAD51D, and STK11 (mderate penetrance). Gupta et al. (2017) nted that high r mderate penetrance genes with published guidelines r recmmendatins fr risk management/surveillance included APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53, POLD1, GREM1, and POLE. Bth authrs nted that these lists are nt an endrsement by NCCN f specific genes r panels, but was prvided fr educatinal purpses t aid clinicians in selecting an apprpriate panel fr their patients. Crawfrd et al (2017) tested 300 wmen wh previusly tested negative fr BRCA1/2. All f the subjects met additinal criteria including: a persnal histry f bilateral Breast Cancer; r a persnal histry f Breast Cancer and a first r secnd degree relative with varian cancer; r a persnal histry f varian, fallpian tube, r peritneal carcinma. The testing determined that 9% f wmen had pathgenic mutatins and 8% had mutatins in genes ther than BRCA1/BRCA2. The researchers cncluded that individuals with additinal criteria may be candidates fr additinal multi-gene panel testing which has imprtant implicatins fr family testing. An analysis f 252,223 individuals by a 25-gene pan-cancer panel was perfrmed by Rsenthal et al. (2017). Of these individuals, the majrity (92.8%) met testing criteria fr Hereditary Breast and Ovarian Cancer (HBOC) and/r Lynch syndrme (LS). Pathgenic variants were identified in 6.7% f the tested individuals with BRCA1/2 (42.2%), ther Breast Cancer (BR) genes (32.9%), and the LS genes (13.2%). Hwever, half f the pathgenic variants in individuals wh met nly HBOC criteria were in nn-brca1/2 genes. Likewise, in individuals wh met LS criteria, half f the pathgenic variants identified were in nn-ls genes. These researchers suggest that a pan-cancer panel may prvide imprved identificatin f pathgenic variants ver single-syndrme testing. Lincln et al. (2015) tested 1105 individuals using a 29-gene next-generatin sequencing panel. The 1105 cases included 1062 clinical cases (735 patients prspectively accrued fllwing NCCN guidelines fr HBOC, 118 patients with knwn familial mutatins, 209 patients retrspectively cllected with high-risk criteria). Of the 1062 clinical cases, 975 had previusly received BRCA1/2 testing and the results shwed a cncrdance f 99.8%. Overall, 260 variants were determined. The 735 prspective patients had 66 patients (9.0%) with a BRCA1 r BRCA2 variant. Twenty-six patients (3.9%) were BRCA-negative, but had variants in ther genes with knwn assciated t breast/varian cancer r thse assciated with Lynch syndrme. Mst cmmn nn-brca findings were ATM (five cases), PALB2 (five cases), CHEK2 (three cases), and the Lynch syndrme genes (eight cases). Anther 2.7% f these BRCA-negative patients were carriers f MUTYH. The high-risk patients (n=2009) were determined t have BRCA1 r BRCA2 in 40% f the patients and f the BRCA-negative individuals, 6.1% were psitive f anther variant. The researchers fund that variants f uncertain significance (VUS) increased as the number f genes was tested. Of the 1062 clinical cases, 41.0% had at least ne VUS and f thse 11.4% had tw r mre. Additinally, 68% f the VUS detected were rare, missense variants that were nt identified in the 1000Genmes Prject. They cncluded that NGS testing f panels can ffer results that may be missed by traditinal testing, but the issue with understanding and addressing VUS remains a challenge. Zhang et al. (2015) studied the prevalence f cancer pre-dispsitin germline mutatins in children and adlescents with cancer in 1,120 patients under the age f 20. Whle exmes were sequenced in 456 patients and whle genmes were sequenced in 595, r bth in 69. Results were analyzed in 565 genes, including 60 that are assciated with autsmal dminant cancer syndrmes. Genetic variant pathgenicity was determined by a team f experts wh relied n peer reviewed literature, cancer and lcus specific databases, cmputatinal predictins, and secnd hits identified in the participant tumr genme. This same variant calling apprach was used t analyze data n 966 cntrls frm the 1000 Genmes Prjects wh were nt knwn t have cancer, and data frm 733 children frm an autism study. Overall, germline mutatins were fund in 95 children with cancer (8.5%), as cmpared t nly 1.1% f 1000 Genme Prject and 0.6% f autism study cntrls. The mutatins were mst cmmnly fund in TP53, APC, BRCA2, NF1, PMS2, RB1 and RUNX3. Eighteen patients als have variants in tumr suppressr genes. Of the 58 patients wh had family histry infrmatin available and a mutatin in a predispsing dminant cancer gene, 40% had a significant family histry f cancer. Parsns et. Al (2016) cnducted a study t determine the prevalence f smatic and germline mutatins in children with slid tumrs. Frm August 2012 thrugh June 2014, children with newly diagnsed and previusly untreated central nervus system (CNS) and nn-cns slid tumrs were prspectively enrlled in the study at a large academic children s hspital. Bld and tumr samples underwent whle exme sequencing (WES) in a certified clinical labratry with genetic results categrized by clinical relevance. A ttal f 150 children participated, with a mean age f 7 years, with 80 bys and 70 girls. Tumr samples were available fr WES in 121 patients. In this grup, smatic Genetic Testing fr Hereditary Cancer Page 12 f 23 UnitedHealthcare Oxfrd Clinical Plicy Effective 10/01/ , Oxfrd Health Plans, LLC
GENETIC TESTING FOR HEREDITARY CANCER
Oxfrd UnitedHealthcare Oxfrd Clinical Plicy GENETIC TESTING FOR HEREDITARY CANCER Plicy Number: DIAGNOSTIC 004.30 T2 Effective Date: January 1, 2019 Instructins fr Use Table f Cntents Page CONDITIONS OF
More informationBRCA1, BRCA2 and PALB2 Testing for Breast, Ovarian and Other Cancers
Plicy Medical Plicy Manual Draft Revised Plicy: D Nt Implement BRCA1, BRCA2 and PALB2 Testing fr Breast, Ovarian and Other Cancers DESCRIPTION Hereditary breast and varian cancer (HBOC) syndrme describes
More informationTriple negative breast cancer Diagnosed at any age with: o
Last Review Date: February 9, 2018 Number: MG.MM.LA.08h Medical Guideline Disclaimer Prperty f EmblemHealth. All rights reserved. The treating physician r primary care prvider must submit t EmblemHealth
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationVIRGINIA OBSTETRICS & GYNECOLOGY, P.C.
VIRGINIA OBSTETRICS & GYNECOLOGY, P.C. 19490 Sandridge Way Suite 350 Leesburg, VA 20176 Phne (703) 858-5599 Fax (703) 858-5699 PERSONAL INFORMATION: PATIENT INFORMATION SHEET Please Print Date. Patient's
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationPolicy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning
Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening
More informationGENETIC TESTING FOR HEREDITARY CANCER
UnitedHealthcare Oxford Clinical Policy GENETIC TESTING FOR HEREDITARY CANCER Policy Number: DIAGNOSTIC 004.27 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationProtocol. Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome
(20402, 204126) Medical Benefit Effective Date: 01/01/18 Next Review Date: 09/18 Preauthrizatin Yes Review Dates: 02/07, 01/08, 11/08, 09/09, 05/10, 05/11, 01/12, 01/13, 01/14, 05/14, 05/15, 05/16, 09/16,
More informationGenetic Testing for Hereditary Breast and/or Ovarian Cancer. Original Policy Date
MP 2.04.01 Genetic Testing fr Hereditary Breast and/r Ovarian Cancer Medical Plicy Sectin Medicine Issue 12:2013 Original Plicy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationSpecifically, on page 12 of the current evicore draft, we find the statement:
Octber 23, 2016 evicre Healthcare Attn: Dr Greg Allen 400 Buckwalter Place Bulevard Blufftn, SC 29910 RE: evicre Draft Onclgy Imaging Guidelines, v 19.0 Gentlepersns: Prstate Cancer Internatinal is a nt-fr-prfit
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationGenetic Testing for FAP and Lynch Syndrome
nuated Prtcl Genetic Testing fr FAP and Lynch Syndrme (20408) Medical Benefit Effective Date: 01/01/17 Next Review Date: 09/18 Preauthrizatin Yes Review Dates: 01/10, 01/11, 01/12, 01/13, 01/14, 01/15,
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling
More informationPodcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10
Pdcast Transcript Title: Cmmn Miscding f LARC Services Impacting Revenue Speaker Name: Ann Finn Duratin: 00:16:10 NCTCFP: Welcme t this pdcast spnsred by the Natinal Clinical Training Center fr Family
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More information2. How are screening and diagnostic mammograms different?
Mammgrams cmprises public dmain material frm the Natinal Cancer Institute at the Natinal Institutes f Health, an agency f the U.S. Department f Health and Human Services. Mammgrams Key Pints A mammgram
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationThe data refer to persons aged between 15 and 54.
Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationSPINRAZA (NUSINERSEN)
SPINRAZA (NUSINERSEN) UnitedHealthcare Oxfrd Clinical Plicy Plicy Number: PHARMACY 295.4 T2 Effective Date: April 1, 2018 Table f Cntents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE... 1 BENEFIT
More informationThe estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by
ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationHealth Science Ch. 16 Cancer Lecture Outline
Cancer Leading cause f disease-related death amng peple under age 75 Secnd leading cause f death Evidence supprts that mst cancers culd be prevented by simple lifestyle changes Tbacc is respnsible fr abut
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationIowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training
Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationACRIN 6666 Screening Breast US Follow-up Assessment Form
Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related
More informationPrevention Checklist for Men
Page 1 f 5 Preventin Checklist fr Men A lt f prgress has been made in cancer research, but we still dn t understand exactly what causes mst cancers. We d knw that many factrs put us at higher risk fr different
More informationPET FORM Planning and Evaluation Tracking ( Assessment Period)
Divisin f: Behaviral Studies PET FORM Planning and Evaluatin Tracking (2010 2011 Assessment Perid) Persn Respnsible fr this Divisin: Jerry Mller Department f: Behaviral Sciences Persn Respnsible fr this
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationCHEMOPREVENTION in BREAST CANCER
CHEMOPREVENTION in BREAST CANCER Ozlem Er, M.D. Assc Prf f Medical Onclgy ESMO Curse Essentials f Medical Onclgy Outline Risk Assessment Mlecular Targets ER psitive Breast Cancer Tamxifen Ralxifene Lasfxifene
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More informationNonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer
Nnclinical factrs assciated with premature terminatin f adjuvant chemtherapy fr stage I-III breast cancer Xia-Cheng Wu, Trevr Thmpsn, Meichin Hsieh, Meijia Zhu, Patricia Andrews, Michelle Lch, Timthy Styles,
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing f BRCA1 and BRCA2 Genes MP9478 Covered Service: Pri Authization Required: Additional Infmation: Yes when meets criteria below Yes--as shown below Pre and post-test genetic counseling is
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationHIP REPLACEMENT SURGERY (ARTHROPLASTY)
Prtcl: ORT015 Effective Date: June 1, 2017 HIP REPLACEMENT SURGERY (ARTHROPLASTY) Table f Cntents Page COMMERCIAL & MEDICAID COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE... 3 U.S.FOOD AND DRUG ADMINISTRATION
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationEvaluation of a Shared Decision Making Intervention between Patients and Providers to Improve Menopause Health Outcomes: Issue Brief
Evaluatin f a Shared Decisin Making Interventin between Patients and Prviders t Imprve Menpause Health Outcmes: Issue Brief Key Findings Tablet technlgy can be successfully incrprated int primary practices
More informationEXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS
1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationContinuous or Intermittent Monitoring of Glucose in Interstitial Fluid
Medical Plicy 1.01.20 Cntinuus r Intermittent Mnitring f Glucse in Interstitial Fluid Sectin 1.0 Durable Medical Equipment Subsectin Effective Date February 27, 2015 Original Plicy Date February 23, 2000
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.
27 March 2014 Prfessr Debra Picne Chief Executive Officer Australian Cmmissin n Safety and Quality in Health Care c/ Ms Jennifer Hill, Senir Prject Officer Level 5, 255 Elizabeth Street SYDNEY NSW 2000
More informationPublic consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking
Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationIndependent Charitable Patient Assistance Program (IPAP) Code of Ethics
Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin
More informationA pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.
NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationPSYCHOSEXUAL ASSESSMENTS for Children and Adolescents with Problematic Sexual Behavior. Who is qualified to conduct a psychosexual evaluation?
PSYCHOSEXUAL ASSESSMENTS fr Children and Adlescents with Prblematic Sexual Behavir When a child r adlescent is suspected r bserved t have engaged in what may be sexually inapprpriate r sexually aggressive
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationFTD RESEARCH: The Value of Studies and Opportunities for Involvement
FTD RESEARCH: The Value f Studies and Opprtunities fr Invlvement Sarah Lawrence, MS Research Prgram Manager Ann Fishman, MBA Sr. Research Crdinatr Weiyi Mu, ScM Genetic Cunselr Suzanne Dana Spuse/Caregiver
More informationField Epidemiology Training Program
Field Epidemilgy Training Prgram Cancer Curriculum: Principles f Cancer Registries Case Study: Hspital-Based Cancer Registries FACILITATOR GUIDE FETP Cancer Curriculum: Principles f Cancer Registries Case
More informationAnnual Principal Investigator Worksheet About Local Context
Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationStudy Design Open, three arm-stratified, non-randomized, prospective, multicentric study
PONS Study Synpsis Title f the Study Subtype-Stratified Fllw-up Care Study f Breast Cancer Patients with Cmbined In Vitr and In Viv Diagnstics Plus Early Target-Oriented Interventin Gals Imprve and individualize
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationReliability and Validity Plan 2017
Reliability and Validity Plan 2017 Frm CAEP The principles fr measures used in the CAEP accreditatin prcess include: (a) validity and reliability, (b) relevance, (c) verifiability, (d) representativeness,
More information2016 CWA Political Action Fund Administrative Procedures Checklist
2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year
More informationHearing Service Fees and Fee Codes Effective: January 01, 2019
Hearing Fees and Fee Cdes Effective: January 01, 2019 The WCB will fund the fllwing hearing services fr claims accepted fr traumatic and ccupatinal nise induced hearing: Fee cde 200 - Full audilgical assessment.
More information2018 Medical Association Poster Symposium Guidelines
2018 Medical Assciatin Pster Sympsium Guidelines Overview The 3 rd Annual student-run Medical Assciatin f the State f Alabama Research Sympsium will take place n Friday and Saturday, April 13-14 at the
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationD E R B Y, D E R B Y S H I R E, N O T T I N G H A M & N O T T I N G H A M S H I R E L M I S U M M A R Y
D E R B Y, D E R B Y S H I R E, N O T T I N G H A M & N O T T I N G H A M S H I R E L M I S U M M A R Y 2 A B O U T This dcument prvides a summary f key findings fr the Derby, Derbyshire, Nttingham and
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationWCPT awards programme 2015
WCPT awards prgramme 2015 The WCPT awards prgramme recgnises utstanding cntributins and leadership by individual physical therapists and grups t the prfessin and/r glbal health at an internatinal level.
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated
More informationMedicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes
Medicare Advantage 2019 Advance Ntice Part 1 21 st Century Cures Act Methdlgical Changes Review f Relevant Prvisins with Expert Insight January 2018 PULSE8 is privileged t bring yu a summary f key Medicare
More information